Common clinical manifestations of TA-TMA
| . | Adulta . | Pediatrica . |
|---|---|---|
| Renal | ||
| Acute kidney injury | 41% | 61% |
| Hypertension | 32% | Common (% not reported) |
| Proteinuria >30 mg/dL | 68% | 76% |
| Neurologic | ||
| Encephalopathy, confusion, or seizure | 25% | 23% |
| Gastrointestinal | ||
| Preceding/concurrent acute GVHDb | 49% | 38% |
| Gastrointestinal bleeding | 8% | 25% |
| Cardiopulmonary | ||
| Diffuse alveolar hemorrhage | 9% | 17%c |
| Pericardial effusion | Not reported | 18% |
| Pulmonary hypertension | Not reported | 7% |
| . | Adulta . | Pediatrica . |
|---|---|---|
| Renal | ||
| Acute kidney injury | 41% | 61% |
| Hypertension | 32% | Common (% not reported) |
| Proteinuria >30 mg/dL | 68% | 76% |
| Neurologic | ||
| Encephalopathy, confusion, or seizure | 25% | 23% |
| Gastrointestinal | ||
| Preceding/concurrent acute GVHDb | 49% | 38% |
| Gastrointestinal bleeding | 8% | 25% |
| Cardiopulmonary | ||
| Diffuse alveolar hemorrhage | 9% | 17%c |
| Pericardial effusion | Not reported | 18% |
| Pulmonary hypertension | Not reported | 7% |
Clinical manifestation in selective retrospective cohorts with at least 50 TA-TMA patients or prospective studies 2014-2023: adult—Gavriilaki 2018 (n = 116), Kraft 2019 (n = 65), Li 2019 (n = 192), Heybeli 2020 (n = 84); pediatric—Jodele 2014 (n = 39), Dandoy 2021 (n = 98), Agarwal 2022 (n = 58). Studies that presented data on all TA-TMA patients at initial diagnosis (instead of selective high-risk or low-risk subset) were included.
Either grade 2 to 4 or 1 to 4 depending on the study included; not all GVHDs were gastrointestinal.
Number of patients with DAH within 2 weeks of TA-TMA diagnosis.